CING Key Statistics, Chart & Performance
The current stock price of CING is 4.6224 USD. In the past month the price increased by 20.56%. In the past year, price decreased by -1.25%.
CING Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.27 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 495.04B | ||
| MRK | MERCK & CO. INC. | 12.38 | 270.66B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.30B | ||
| ZTS | ZOETIS INC | 20.37 | 56.91B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.87 | 23.42B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.58 | 11.72B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.59B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.60B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.38B |
Related stock screener links
About CING
Company Profile
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Company Info
CINGULATE INC
1901 W. 47Th Place
Kansas City KANSAS US
Employees: 13
Phone: 19139422300
CINGULATE INC / CING FAQ
Can you describe the business of CINGULATE INC?
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
What is the current price of CING stock?
The current stock price of CING is 4.6224 USD. The price decreased by -2.69% in the last trading session.
Does CINGULATE INC pay dividends?
CING does not pay a dividend.
How is the ChartMill rating for CINGULATE INC?
CING has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for CINGULATE INC?
CINGULATE INC (CING) has a market capitalization of 31.25M USD. This makes CING a Nano Cap stock.
CING Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CING. When comparing the yearly performance of all stocks, CING turns out to be only a medium performer in the overall market: it outperformed 57.77% of all stocks.
CING Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CING. Both the profitability and financial health of CING have multiple concerns.
CING Financial Highlights
Over the last trailing twelve months CING reported a non-GAAP Earnings per Share(EPS) of -7.5. The EPS increased by 92.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -209.76% | ||
| ROE | -635.19% | ||
| Debt/Equity | 0.92 |
CING Forecast & Estimates
9 analysts have analysed CING and the average price target is 27.95 USD. This implies a price increase of 504.62% is expected in the next year compared to the current price of 4.6224.